RESUMO
OBJECTIVE: Nasopharyngeal carcinoma (NPC) is one of the most ordinary head and neck tumors. This study aims to uncover the role of circ-ABCB10 functions in the progression of NPC. PATIENTS AND METHODS: The circ-ABCB10 expression was detected in paired NPC patients' tissue samples and cell lines. The role of circ-ABCB10 in NPC proliferation was identified through proliferation assay, Ethynyl deoxyuridine (EdU) assay and colony formation assay. Next, the role of circ-ABCB10 in NPC metastasis was measured through wound healing assay and transwell assay. Finally, the underlying mechanism was further uncovered through Western blot assay and real-time quantitative polymerase chain reaction (RT-qPCR). RESULTS: It was found that circ-ABCB10 expression was significantly higher in NPC tissues than that in adjacent samples. In addition, cell proliferation, migration and invasion of NPC were promoted through overexpression of circ-ABCB10 in vitro. Results of further experiments revealed that ROCK1 was upregulated via overexpression of circ-ABCB10 in NPC. CONCLUSIONS: This study indicated that circ-ABCB10 promoted NPC cell proliferation and metastasis via upregulating ROCK1 in vitro.
Assuntos
Carcinoma Nasofaríngeo/metabolismo , Neoplasias Nasofaríngeas/metabolismo , RNA Circular/metabolismo , Regulação para Cima , Quinases Associadas a rho/metabolismo , Proliferação de Células , Células Cultivadas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Carcinoma Nasofaríngeo/patologia , Neoplasias Nasofaríngeas/patologia , RNA Circular/genética , Quinases Associadas a rho/genéticaAssuntos
Mucosa Gástrica , Neoplasias Gastrointestinais , Mucosa Intestinal , Linfoma , Humanos , Tecido LinfoideRESUMO
The aim of this meta-analysis was to investigate the overall diagnostic and prognostic values of CTHRC1 expression in human cancer development. Based on the inclusion and exclusion criteria, 8 cohort studies were included in the meta-analysis. The data were extracted, and analyses were performed using a random-effects model. Summary odds ratios (ORs) and effect sizes (ESs) with 95% confidence intervals (CIs) were calculated to assess the strength of the associations. A total of 1065 cancer patients from the 8 studies were included in the meta-analysis. The results revealed a positive correlation of CTHRC1 protein expression in tumors with tumor-node-metastasis (TNM) stage and with lymph node (LN) metastasis (TNM: OR = 2.98, 95%CI = 1.48-6.00, P = 0.002; LN: OR = 4.26, 95%CI = 1.88-9.67, P = 0.001). CTHRC1 expression was higher in tumors with sizes ≥5 cm than in tumors with sizes <5 cm (OR = 2.39, 95%CI = 1.12-5.09, P = 0.024). Patients with higher CTHRC1 expression had decreased overall survival (OS) (ES = 1.78, 95%CI = 1.23-2.33, P < 0.001) and poorer disease-free survival (DFS) (ES = 1.71, 95%CI = 1.11-2.31, P < 0.001). Disease-stratified analyses yielded significantly different estimates of CTHRC1 levels in the majority of the subgroups (all P < 0.05). In conclusion, increased CTHRC1 expression is associated with advanced TNM stage, increased LN metastasis and tumor size, and decreased OS and DFS, indicating that CTHRC1 may be a biomarker for prognosis of cancer patients.